Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies
BACKGROUND: Plasmodium vivax is the most widespread human malaria geographically; however, no effective vaccine exists. Red blood cell invasion by the P. vivax merozoite depends on an interaction between the Duffy antigen receptor for chemokines (DARC) and region II of the parasite's Duffy-bind...
Main Authors: | Payne, R, Silk, S, Elias, S, Milne, K, Rawlinson, T, Llewellyn, D, Shakri, A, Jin, J, Labbé, G, Edwards, N, Poulton, I, Roberts, R, Farid, R, Jørgensen, T, Alanine, D, de Cassan, S, Higgins, M, Otto, T, McCarthy, J, de Jongh, W, Nicosia, A, Moyle, S, Hill, A, Berrie, E, Chitnis, C, Lawrie, A, Draper, S |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American Society for Clinical Investigation
2017
|
Similar Items
-
Preclinical assessment of viral vectored and protein vaccines targeting the Duffy-binding protein region II of Plasmodium vivax
by: de Cassan, SC, et al.
Published: (2015) -
Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.
by: Hodgson, S, et al.
Published: (2014) -
Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection
by: Hou, M, et al.
Published: (2023) -
Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development
by: Mertens, JE, et al.
Published: (2024) -
Duffy's friend (poster)
by: Clerkenwell Theatre, CT
Published: (2006)